SCHEMBL330156

SCHEMBL330156

CC(=O)Oc1ccc(Cl)cc1C(=O)Nc1cc(C(C)(C)C)cc(C(C)(C)C)c1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 1/20 0.60
ALDH1A1 P00352 1/20 0.53
P2RX1 P51575 3/20 0.53
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
P2RX4 Q99571 2/20 0.50
P2RX7 Q99572 2/20 0.50
TMPRSS4 Q9NRS4 2/20 0.50
IKBKB O14920 1/20 0.50
CHUK O15111 1/20 0.50
KDR P35968 1/20 0.50
FLT3 P36888 1/20 0.50
MYLK Q15746 1/20 0.50
MAP4K5 Q9Y4K4 1/20 0.50
KCNMA1 Q12791 1/20 0.49
NPC1 O15118 1/20 0.47
POLB P06746 1/20 0.47
AHR P35869 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL130511 0.89 TMPRSS4 (0.65) NR1H4ALDH1A1P2RX1MEN1KMT2A
SCHEMBL16707260 0.87 TMPRSS4 (0.60) NR1H4ALDH1A1P2RX1MEN1KMT2A
SCHEMBL329943 0.81 KCNMA1 (0.55) NR1H4ALDH1A1MEN1KMT2AKCNMA1
SCHEMBL330263 0.80 P2RX1 (0.78) P2RX1MEN1KMT2AP2RX4P2RX7
SCHEMBL4498846 0.80 TMPRSS4 (0.62) ALDH1A1P2RX1MEN1KMT2AP2RX4
SCHEMBL3497425 0.78 TMPRSS4 (0.64) ALDH1A1P2RX1MEN1KMT2AP2RX4
SCHEMBL3281999 0.78 RHOC (0.56) P2RX1MEN1KMT2AP2RX4P2RX7
SCHEMBL330635 0.76 TRPV1 (0.59) NR1H4ALDH1A1P2RX1MEN1KMT2A
SCHEMBL3691064 0.76 KMT2A (0.61) NR1H4ALDH1A1MEN1KMT2AKCNMA1
SCHEMBL16709939 0.76 TMPRSS4 (0.68) ALDH1A1P2RX1MEN1KMT2AP2RX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263657-B2 Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2012-09-11 US disclosed
US-8097759-B2 Inflammatory cytokine release inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2012-01-17 US disclosed
US-20100274051-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2010-10-28 US disclosed
US-20090192122-A2 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-07-30 US disclosed
US-20080318956-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2008-12-25 US disclosed
US-20080249071-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2008-10-09 US disclosed
EP-1847263-A2 Inhibitors against the production and release of inflammatory cytokines Institute of Medicinal Molecular Design, Inc. (JP) 2007-10-24 EP disclosed
EP-1844766-A2 Inhibitors against the production and release of inflammatory cytokines Institute of Medicinal Molecular Design, Inc. (JP) 2007-10-17 EP disclosed
US-20040259877-A1 Inhibitors against the production and release of inflammatory cytokines INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2004-12-23 US disclosed
EP-1352650-A1 INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES Institute of Medicinal Molecular Design, Inc. (JP) 2003-10-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100274051-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR IL1B, NFKBIA, IL1A NR1H4 1575/4885ALDH1A1 479/4885P2RX1 1459/4885
US-20090192122-A2 INFLAMMATORY CYTOKINE RELEASE INHIBITOR IL1B, NFKBIA, IL1A NR1H4 1508/4885ALDH1A1 563/4885P2RX1 1538/4885
US-20080249071-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR IL1B, NFKBIA, IL1A NR1H4 1508/4885ALDH1A1 563/4885P2RX1 1538/4885
US-20080318956-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR IL1B, NFKBIA, IL1A NR1H4 1508/4885ALDH1A1 563/4885P2RX1 1538/4885
US-20040259877-A1 Inhibitors against the production and release of inflammatory cytokines NFKBIA, IL1B, IKBKB NR1H4 2138/4885ALDH1A1 1025/4885P2RX1 2316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.